Abstract
Cytarabine plays a pivotal role in chemotherapy for adult acute myeloid leukemia (AML). For all AML adult patients, especially core binding factor (CBF) AML adult patients, and AML adult patients with t(8; 21)(q22; q22) karyotype and inv(16)/t(16; 16) karyotype, application of 4 courses of high dose of cytarabine (HDAC) can effectively improve the prognosis. AML adult patients with RAS mutation also tend to benefit from HDAC. However, in the consolidation chemotherapy in AML adult patients, issues like optimal course of treatment, cumulative dose, single drug or multiagent chemotherapy (MCT) of cytarabine are still being explored. With the application of newly-developed drugs as targeting certain gene mutations, treatment regimens of cytarabine still need to be optimized. This article focuses on application research progress of cytarabine in the consolidation chemotherapy of AML adult patients and its studying current status. Key words: Leukemia, myeloid, acute; Cytarabine; Drug therapy; Antineoplastic combined chemotherapy protocol
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Blood Transfusion and Hematology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
